Following the registration of the corresponding amendment to its Articles of Association in the Commercial Register, Darwin AG has officially changed its name to Novogenia AG, effective immediately. The name change follows a resolution passed at the Annual General Meeting on June 26, 2026, and marks a strategic move to unify the company's corporate and brand identities under the Novogenia name.
The decision to rename the company reflects its strategic focus on its core operating brand, Novogenia GmbH, which has been the primary driver of the group's operational business and future growth. Novogenia GmbH has been active in human genetics for many years, developing and selling personalized products based on genetic analysis. The Novogenia brand is synonymous with in-depth scientific expertise and ongoing technological innovation in the field of personalized healthcare and longevity solutions.
According to Dr. Daniel Wallerstorfer, CEO of Novogenia AG, "Novogenia has been at the heart of our operational business and our international market presence for many years. By operating under the name Novogenia AG, we are consistently unifying our corporate and brand identities. This enhances the visibility and recognition of our Group while reinforcing our ambition to establish Novogenia as a leading international provider of personalized healthcare and longevity solutions, as well as a strong and recognizable brand in the capital market."
The name change simplifies the corporate structure and communication, creating a consistent image across all relevant target groups, including customers, business partners, investors, and the broader international community. It supports a clearer positioning in the capital market. Importantly, the renaming has no impact on the company's strategic direction, business model, or operational activities. The stock market listing and existing shareholder rights remain unchanged.
Novogenia AG, headquartered in Munich, Germany, is a European healthcare company active in human genetics and the development of personalized products based on genetic analysis. The company's genetic analyses, conducted in its own laboratory, are used in the diagnosis, treatment, and prevention of diseases, as well as in the production of individually tailored nutritional supplements and cosmetics. Novogenia also partners with physicians, therapists, pharmacists, nutritionists, and fitness trainers to optimize treatment based on genetic predispositions. Additionally, the company holds investments in innovative biotech, healthcare, and life sciences companies. For more information, visit https://novogenia.com/novogenia-ag.
